NOD2 and myeloid sarcoma: Following our previous findings that a MNCs from a subgroup of MS patients respond to challenge with MBP ex vivo with CD4+ T-cell proliferation and production of IL-17, IFN-γ, IL-5 and IL-4 [18], we have here examined whether these responses are associated with the three most common NOD2 mutations.